Subtype
Soft Tissue Neoplasm of Uncertain Differentiation
CI-CAN-00001532Explore in graph →
Non-malignant74 active trials2 approved drugs38 evidence items
- NCIt
- C7148
Loading cancer entity…
Subtype
CI-CAN-00001532Explore in graph →
Clinical trials
241 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | withdrawn | Phase 2 | 0 | Situs Cancer Research CenterOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT04906876 |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas |
| withdrawn |
| Phase 2 |
| 0 |
| Brown UniversityOTHER |
| 1 |
| Jul 28, 2021 |
| clinicaltrials |
| NCT01690871 | A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
Data updated 23 days agoSource updated May 18, 2025source: clinicaltrials